A novel method to address the association between received dose intensity and survival outcome: benefits of approaching treatment intensification at a more individualised level in a trial of the European Osteosarcoma Intergroup

Author(s):
Lancia, C.; Anninga, J.K.; Sydes, M.R.; Spitoni, C.; Whelan, J.; Hogendoorn, P.C.W. (0000-0002-1513-8104); Gelderblom, H.; Fiocco, M.
Published
2019
Publication type
Article / Letter to editor
Bone tumourSarcomaChemotherapyPersonalised medicine
Date issued
2019-05-31
Language
English
Is part of
Cancer Chemotherapy and Pharmacology (2019), Vol. 83, no. 5, p. 951-962
hdl
1887/121132
doi
10.1007/s00280-019-03797-3